- Home
- SCOR vs RNXT Comparison
SCOR vs RNXT Comparison
Compare SCOR & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCOR | RNXT |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 32.5M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCOR | RNXT |
|---|---|---|
| Price | $7.08 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 16.5K | ★ 350.1K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $358,940,000.00 | $928,000.00 |
| Revenue This Year | $2.01 | $2,895.35 |
| Revenue Next Year | $1.57 | $313.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $4.39 | $0.70 |
| 52 Week High | $10.18 | $1.69 |
Technical Indicators
Market Signals| Indicator | SCOR | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 53.81 | 51.53 |
| Support Level | $6.40 | $0.81 |
| Resistance Level | $7.10 | $0.93 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 84.85 | 96.29 |
Price Performance
Historical ComparisonAbout SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.